These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

395 related articles for article (PubMed ID: 28319809)

  • 1. ABT-737 Synergizes with Cisplatin Bypassing Aberration of Apoptotic Pathway in Non-small Cell Lung Cancer.
    Kim EY; Jung JY; Kim A; Chang YS; Kim SK
    Neoplasia; 2017 Apr; 19(4):354-363. PubMed ID: 28319809
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cisplatin-induced apoptosis in non-small-cell lung cancer cells is dependent on Bax- and Bak-induction pathway and synergistically activated by BH3-mimetic ABT-263 in p53 wild-type and mutant cells.
    Matsumoto M; Nakajima W; Seike M; Gemma A; Tanaka N
    Biochem Biophys Res Commun; 2016 Apr; 473(2):490-6. PubMed ID: 26996126
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting BCL-2 family proteins to overcome drug resistance in non-small cell lung cancer.
    Wesarg E; Hoffarth S; Wiewrodt R; Kröll M; Biesterfeld S; Huber C; Schuler M
    Int J Cancer; 2007 Dec; 121(11):2387-94. PubMed ID: 17688235
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined antitumor effect of γ-secretase inhibitor and ABT-737 in Notch-expressing non-small cell lung cancer.
    Sakakibara-Konishi J; Ikezawa Y; Oizumi S; Kikuchi J; Kikuchi E; Mizugaki H; Kinoshita I; Dosaka-Akita H; Nishimura M
    Int J Clin Oncol; 2017 Apr; 22(2):257-268. PubMed ID: 27816990
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Platinum compounds sensitize ovarian carcinoma cells to ABT-737 by modulation of the Mcl-1/Noxa axis.
    Simonin K; N'Diaye M; Lheureux S; Loussouarn C; Dutoit S; Briand M; Giffard F; Brotin E; Blanc-Fournier C; Poulain L
    Apoptosis; 2013 Apr; 18(4):492-508. PubMed ID: 23344663
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HSP90 inhibitor (NVP-AUY922) enhances the anti-cancer effect of BCL-2 inhibitor (ABT-737) in small cell lung cancer expressing BCL-2.
    Yang H; Lee MH; Park I; Jeon H; Choi J; Seo S; Kim SW; Koh GY; Park KS; Lee DH
    Cancer Lett; 2017 Dec; 411():19-26. PubMed ID: 28987383
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ABT-737, a BH3 Mimetic, Enhances the Therapeutic Effects of Ionizing Radiation in K-ras Mutant Non-Small Cell Lung Cancer Preclinical Model.
    Lee JM; Kim HS; Kim A; Chang YS; Lee JG; Cho J; Kim EY
    Yonsei Med J; 2022 Jan; 63(1):16-25. PubMed ID: 34913280
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sorafenib Sensitizes Glioma Cells to the BH3 Mimetic ABT-737 by Targeting MCL1 in a STAT3-Dependent Manner.
    Kiprianova I; Remy J; Milosch N; Mohrenz IV; Seifert V; Aigner A; Kögel D
    Neoplasia; 2015 Jul; 17(7):564-73. PubMed ID: 26297434
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ABT-737 synergizes with chemotherapy to kill head and neck squamous cell carcinoma cells via a Noxa-mediated pathway.
    Li R; Zang Y; Li C; Patel NS; Grandis JR; Johnson DE
    Mol Pharmacol; 2009 May; 75(5):1231-9. PubMed ID: 19246337
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BH3 mimetic ABT-737 and a proteasome inhibitor synergistically kill melanomas through Noxa-dependent apoptosis.
    Miller LA; Goldstein NB; Johannes WU; Walton CH; Fujita M; Norris DA; Shellman YG
    J Invest Dermatol; 2009 Apr; 129(4):964-71. PubMed ID: 18987671
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Actinomycin D synergistically enhances the efficacy of the BH3 mimetic ABT-737 by downregulating Mcl-1 expression.
    Olberding KE; Wang X; Zhu Y; Pan J; Rai SN; Li C
    Cancer Biol Ther; 2010 Nov; 10(9):918-29. PubMed ID: 20818182
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bcl-xL inhibition by molecular-targeting drugs sensitizes human pancreatic cancer cells to TRAIL.
    Hari Y; Harashima N; Tajima Y; Harada M
    Oncotarget; 2015 Dec; 6(39):41902-15. PubMed ID: 26506422
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of Bcl-2 and Bcl-X enhances chemotherapy sensitivity in hepatoblastoma cells.
    Lieber J; Kirchner B; Eicher C; Warmann SW; Seitz G; Fuchs J; Armeanu-Ebinger S
    Pediatr Blood Cancer; 2010 Dec; 55(6):1089-95. PubMed ID: 20680965
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Bcl-2 inhibitor ABT-737 enhances the cisplatin-induced apoptosis in breast cancer T47D cells].
    Chen ZJ; Zhang B; Pan SH; Zhao HM; Zhang Y; Feng WH; Li YY; Cao XC
    Zhonghua Zhong Liu Za Zhi; 2011 Dec; 33(12):891-5. PubMed ID: 22340096
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of Bcl-2 family members on the cellular response of small-cell lung cancer cell lines to ABT-737.
    Tahir SK; Yang X; Anderson MG; Morgan-Lappe SE; Sarthy AV; Chen J; Warner RB; Ng SC; Fesik SW; Elmore SW; Rosenberg SH; Tse C
    Cancer Res; 2007 Feb; 67(3):1176-83. PubMed ID: 17283153
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Bcl-xL inhibitor, ABT-737, efficiently induces apoptosis and suppresses growth of hepatoma cells in combination with sorafenib.
    Hikita H; Takehara T; Shimizu S; Kodama T; Shigekawa M; Iwase K; Hosui A; Miyagi T; Tatsumi T; Ishida H; Li W; Kanto T; Hiramatsu N; Hayashi N
    Hepatology; 2010 Oct; 52(4):1310-21. PubMed ID: 20799354
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A small molecule pan-Bcl-2 family inhibitor, GX15-070, induces apoptosis and enhances cisplatin-induced apoptosis in non-small cell lung cancer cells.
    Li J; Viallet J; Haura EB
    Cancer Chemother Pharmacol; 2008 Mar; 61(3):525-34. PubMed ID: 17505826
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dihydroartemisinin suppresses STAT3 signaling and Mcl-1 and Survivin expression to potentiate ABT-263-induced apoptosis in Non-small Cell Lung Cancer cells harboring EGFR or RAS mutation.
    Yan X; Li P; Zhan Y; Qi M; Liu J; An Z; Yang W; Xiao H; Wu H; Qi Y; Shao H
    Biochem Pharmacol; 2018 Apr; 150():72-85. PubMed ID: 29360439
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ionizing radiation sensitizes breast cancer cells to Bcl-2 inhibitor, ABT-737, through regulating Mcl-1.
    Wu H; Schiff DS; Lin Y; Neboori HJ; Goyal S; Feng Z; Haffty BG
    Radiat Res; 2014 Dec; 182(6):618-25. PubMed ID: 25409124
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Bcl-2/Bcl-XL family inhibitor ABT-737 sensitizes ovarian cancer cells to carboplatin.
    Witham J; Valenti MR; De-Haven-Brandon AK; Vidot S; Eccles SA; Kaye SB; Richardson A
    Clin Cancer Res; 2007 Dec; 13(23):7191-8. PubMed ID: 18056200
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.